We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Viking Therapeutics, Inc. (VKTX) Declines More Than Market: Some Information for Investors
Read MoreHide Full Article
In the latest trading session, Viking Therapeutics, Inc. (VKTX - Free Report) closed at $29.94, marking a -7.95% move from the previous day. The stock fell short of the S&P 500, which registered a loss of 0.4% for the day. Meanwhile, the Dow gained 0.11%, and the Nasdaq, a tech-heavy index, lost 0.73%.
Heading into today, shares of the company had lost 3.9% over the past month, outpacing the Medical sector's loss of 10.07% and the S&P 500's loss of 7.34%.
The upcoming earnings release of Viking Therapeutics, Inc. will be of great interest to investors. In that report, analysts expect Viking Therapeutics, Inc. to post earnings of -$1.01 per share. This would mark a year-over-year decline of 146.34%.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$4.15 per share and revenue of $0 million, indicating changes of -30.09% and 0%, respectively, compared to the previous year.
Investors should also pay attention to any latest changes in analyst estimates for Viking Therapeutics, Inc. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 1.53% downward. Right now, Viking Therapeutics, Inc. possesses a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 150, putting it in the bottom 39% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow VKTX in the coming trading sessions, be sure to utilize Zacks.com.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Viking Therapeutics, Inc. (VKTX) Declines More Than Market: Some Information for Investors
In the latest trading session, Viking Therapeutics, Inc. (VKTX - Free Report) closed at $29.94, marking a -7.95% move from the previous day. The stock fell short of the S&P 500, which registered a loss of 0.4% for the day. Meanwhile, the Dow gained 0.11%, and the Nasdaq, a tech-heavy index, lost 0.73%.
Heading into today, shares of the company had lost 3.9% over the past month, outpacing the Medical sector's loss of 10.07% and the S&P 500's loss of 7.34%.
The upcoming earnings release of Viking Therapeutics, Inc. will be of great interest to investors. In that report, analysts expect Viking Therapeutics, Inc. to post earnings of -$1.01 per share. This would mark a year-over-year decline of 146.34%.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$4.15 per share and revenue of $0 million, indicating changes of -30.09% and 0%, respectively, compared to the previous year.
Investors should also pay attention to any latest changes in analyst estimates for Viking Therapeutics, Inc. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 1.53% downward. Right now, Viking Therapeutics, Inc. possesses a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 150, putting it in the bottom 39% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow VKTX in the coming trading sessions, be sure to utilize Zacks.com.